Shield Therapeutics plc (FRA:1JS)
Germany · Delayed Price · Currency is EUR | Market Cap | 112.71M +266.8% |
| Revenue (ttm) | 42.33M +54.4% |
| Net Income | -15.04M |
| EPS | -0.02 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Average Volume | 20,859 |
| Open | 0.0945 |
| Previous Close | 0.0960 |
| Day's Range | 0.0945 - 0.0945 |
| 52-Week Range | 0.0250 - 0.1470 |
| Beta | n/a |
| RSI | 49.43 |
| Earnings Date | Apr 24, 2026 |
About Shield Therapeutics
Shield Therapeutics plc, a commercial stage specialty pharmaceutical company, focuses on development and commercialization of clinical-stage pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru, a non-salt based oral therapy for adults to treat the iron deficiency with or without anemia. Shield Therapeutics plc was incorporated in 2008 and is based in Gateshead, the United Kingdom. [Read more]
Financial Performance
In 2025, Shield Therapeutics's revenue was $49.70 million, an increase of 54.45% compared to the previous year's $32.18 million. Losses were -$17.66 million, -35.05% less than in 2024.
Financial numbers in USD Financial StatementsNews
OTC Markets Group Welcomes Shield Therapeutics PLC to OTCQX
NEW YORK, May 17, 2021 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 11,000 U.S. and global securities, today announced Shield Therapeutics PLC (LSE: STXS; OT...